Wuhan YZY Biopharma Submits CSRC Filing for H Share Full Circulation
I'm PortAI, I can summarize articles.
Wuhan YZY Biopharma Co., Ltd. has submitted a filing to the China Securities Regulatory Commission (CSRC) for the proposed implementation of H share full circulation, converting 68,010,299 domestic shares into H shares. The process is pending further approvals from the CSRC, Hong Kong Stock Exchange, and other regulatory authorities. Updates will be provided as necessary.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments